File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s12265-014-9580-6
- Scopus: eid_2-s2.0-84906790563
- PMID: 25079593
- WOS: WOS:000340489500001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Endomyocardial Implantation of Autologous Bone Marrow Mononuclear Cells in Advanced Ischemic Heart Failure: a Randomized Placebo-Controlled Trial (END-HF).
Title | Endomyocardial Implantation of Autologous Bone Marrow Mononuclear Cells in Advanced Ischemic Heart Failure: a Randomized Placebo-Controlled Trial (END-HF). |
---|---|
Authors | |
Keywords | Bone marrow cells Heart failure Ischemic cardiomyopathy |
Issue Date | 2014 |
Publisher | Springer New York LLC. The Journal's web site is located at http://www.springer.com/medicine/cardiology/journal/12265 |
Citation | Journal of Cardiovascular Translational Research, 2014, v. 7 n. 6, p. 545-552 How to Cite? |
Abstract | Prior studies suggest that endomyocardial implantation of autologous bone marrow (BM) mononuclear cell therapy improves symptoms and left ventricular (LV) function in patients with refractory angina; however, the therapeutic efficacy in patients with ischemic cardiomyopathy is unclear. In a randomized, double-blind, placebo-controlled trial, 28 patients with advanced ischemic cardiomyopathy [New York Heart Association III-IV, LV ejection fraction (LVEF) <40 %] were assigned in 2:1 ratio to receive endomyocardial injection of BM cells (100 million, n=19) or placebo (n=9), guided by electroanatomical mapping. After 6 months, there was no significant difference between the two groups in LV ejection fraction (LVEF) and LV end-systolic volume (LVESV), LV infarct volume, and LV peri-infarct ischemic volume as determined by cardiac magnetic resonance imaging or exercise capacity. In conclusion, endomyocardial implantation of autologous BM mononuclear cells did not improve LV function or remodeling in patients with advanced ischemic cardiomyopathy. © 2014 Springer Science+Business Media. |
Persistent Identifier | http://hdl.handle.net/10722/203107 |
ISSN | 2023 Impact Factor: 2.4 2023 SCImago Journal Rankings: 0.768 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Santoso, T | - |
dc.contributor.author | Siu, DCW | - |
dc.contributor.author | Irawan, C | - |
dc.contributor.author | Chan, WS | - |
dc.contributor.author | Alwi, I | - |
dc.contributor.author | Yiu, KH | - |
dc.contributor.author | Aziz, A | - |
dc.contributor.author | Kwong, YL | - |
dc.contributor.author | Tse, HF | - |
dc.date.accessioned | 2014-09-19T11:30:49Z | - |
dc.date.available | 2014-09-19T11:30:49Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Journal of Cardiovascular Translational Research, 2014, v. 7 n. 6, p. 545-552 | - |
dc.identifier.issn | 1937-5387 | - |
dc.identifier.uri | http://hdl.handle.net/10722/203107 | - |
dc.description.abstract | Prior studies suggest that endomyocardial implantation of autologous bone marrow (BM) mononuclear cell therapy improves symptoms and left ventricular (LV) function in patients with refractory angina; however, the therapeutic efficacy in patients with ischemic cardiomyopathy is unclear. In a randomized, double-blind, placebo-controlled trial, 28 patients with advanced ischemic cardiomyopathy [New York Heart Association III-IV, LV ejection fraction (LVEF) <40 %] were assigned in 2:1 ratio to receive endomyocardial injection of BM cells (100 million, n=19) or placebo (n=9), guided by electroanatomical mapping. After 6 months, there was no significant difference between the two groups in LV ejection fraction (LVEF) and LV end-systolic volume (LVESV), LV infarct volume, and LV peri-infarct ischemic volume as determined by cardiac magnetic resonance imaging or exercise capacity. In conclusion, endomyocardial implantation of autologous BM mononuclear cells did not improve LV function or remodeling in patients with advanced ischemic cardiomyopathy. © 2014 Springer Science+Business Media. | - |
dc.language | eng | - |
dc.publisher | Springer New York LLC. The Journal's web site is located at http://www.springer.com/medicine/cardiology/journal/12265 | - |
dc.relation.ispartof | Journal of Cardiovascular Translational Research | - |
dc.rights | The final publication is available at Springer via http://dx.doi.org/[insert DOI] | - |
dc.subject | Bone marrow cells | - |
dc.subject | Heart failure | - |
dc.subject | Ischemic cardiomyopathy | - |
dc.title | Endomyocardial Implantation of Autologous Bone Marrow Mononuclear Cells in Advanced Ischemic Heart Failure: a Randomized Placebo-Controlled Trial (END-HF). | - |
dc.type | Article | - |
dc.identifier.email | Siu, DCW: cwdsiu@hkucc.hku.hk | - |
dc.identifier.email | Chan, WS: drwschan@hkucc.hku.hk | - |
dc.identifier.email | Yiu, KH: khkyiu@hku.hk | - |
dc.identifier.email | Kwong, YL: ylkwong@hku.hk | - |
dc.identifier.email | Tse, HF: hftse@hkucc.hku.hk | - |
dc.identifier.authority | Siu, DCW=rp00534 | - |
dc.identifier.authority | Yiu, KH=rp01490 | - |
dc.identifier.authority | Kwong, YL=rp00358 | - |
dc.identifier.authority | Tse, HF=rp00428 | - |
dc.identifier.doi | 10.1007/s12265-014-9580-6 | - |
dc.identifier.pmid | 25079593 | - |
dc.identifier.scopus | eid_2-s2.0-84906790563 | - |
dc.identifier.hkuros | 237968 | - |
dc.identifier.volume | 7 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 545 | - |
dc.identifier.epage | 552 | - |
dc.identifier.isi | WOS:000340489500001 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1937-5387 | - |